Physician profile
Alapatt Thomas
NPI 1386601060
$2,553.32
in general payments reported to CMS, 2019-2025
25 companies · $33.60 in 2025
The $33.60 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,188 · 2020: $332 · 2025: $33.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $428.10 | 2019-2020 | |
| Amarin Pharma, INC. | $366.77 | 2019 | |
| Glaxosmithkline, LLC. | $331.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $283.66 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $147.78 | 2019-2020 | |
| Novo Nordisk INC | $140.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $124.71 | 2019-2020 | |
| Horizon Therapeutics Plc | $98.76 | 2019-2020 | |
| Lilly USA, LLC | $56.55 | 2019 | |
| Boston Scientific Corporation | $33.60 | 2025 | Cds - Mct/Cem Monitoring |
| Zyla Life Sciences, INC. | $28.09 | 2019-2020 | |
| Astellas Pharma US INC | $25.65 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.16 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $19.47 | 2019 | |
| Mannkind Corporation | $15.00 | 2019 | |
| Genentech USA, INC. | $13.85 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.84 | 2019 | |
| Medicure Pharma INC. | $13.61 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.47 | 2019 | |
| Pfizer INC. | $12.32 | 2019 | |
| Hikma Pharmaceuticals USA | $12.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.01 | 2019 | |
| Amgen INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alapatt Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.